Drugs / batabulin
batabulin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00003359 | Apr 1998 → Jan 2001 | cancer of unknown primary site | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00022243 | Oct 2000 → ? | lung cancer | Tularik | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00057382 | Mar 2003 → ? | hepatocellular carcinoma | Tularik | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | batabulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00022243 ↗ |
| Known as | BATABULIN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL79280 ↗ |
| Known as | Batabulina | ChEMBL registry synonym — accepted as the source's own label CHEMBL79280 ↗ |
| Known as | Batabuline | ChEMBL registry synonym — accepted as the source's own label CHEMBL79280 ↗ |
| Known as | T-138067 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL79280 ↗ |
| Known as | T138067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00057382 ↗ |
| Known as | TL 057 | ChEMBL registry synonym — accepted as the source's own label CHEMBL79280 ↗ |
| Modality | Small molecule | — CHEMBL79280 ↗ |
| Route | Intravenous | “Patients receive T138067 sodium by IV over 3 hours.” NCT00003359 ↗ |